A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer
HS Coskun, O Er, M Ozkan, B Eser… - Journal of thrombosis …, 2004 - Wiley Online Library
Background Small cell lung cancer (SCLC) is a chemotherapy‐responsive tumor type but
most patients ultimately experience disease progression. SCLC is associated with …
most patients ultimately experience disease progression. SCLC is associated with …
[引用][C] A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer
M Altinbas, HS Coskun, O Er, M Ozkan, B Eser… - Journal of Thrombosis …, 2004 - cir.nii.ac.jp
A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight
heparin in small cell lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
heparin in small cell lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer.
M Altinbas, HS Coskun, O Er, M Ozkan… - … of Thrombosis and …, 2004 - europepmc.org
Background Small cell lung cancer (SCLC) is a chemotherapy-responsive tumor type but
most patients ultimately experience disease progression. SCLC is associated with …
most patients ultimately experience disease progression. SCLC is associated with …
A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer.
M Altinbas, H Coskun, O Er, M Ozkan… - … of thrombosis and …, 2004 - avesis.erciyes.edu.tr
Background Small cell lung cancer (SCLC) is a chemotherapy-responsive tumor type but
most patients ultimately experience disease progression. SCLC is associated with …
most patients ultimately experience disease progression. SCLC is associated with …
A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer
M Altinbas, HS Coskun, O Er, M Ozkan, B Eser… - Journal of Thrombosis …, 2004 - elibrary.ru
Background Small cell lung cancer (SCLC) is a chemotherapy-responsive tumor type but
most patients ultimately experience disease progression. SCLC is associated with …
most patients ultimately experience disease progression. SCLC is associated with …
[PDF][PDF] A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer
M ALTINBAS, HS COSKUN, O ER… - Journal of Thrombosis …, 2004 - academia.edu
Background Small cell lung cancer (SCLC) is a chemotherapy-responsive tumor type but
most patients ultimately experience disease progression. SCLC is associated with …
most patients ultimately experience disease progression. SCLC is associated with …
A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer
M Altinbas, HS Coskun, O Er… - … of thrombosis and …, 2004 - pubmed.ncbi.nlm.nih.gov
Background Small cell lung cancer (SCLC) is a chemotherapy-responsive tumor type but
most patients ultimately experience disease progression. SCLC is associated with …
most patients ultimately experience disease progression. SCLC is associated with …
[HTML][HTML] A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer
M Altinbas, HS Coskun, O Er, M Ozkan, B Eser… - Journal of Thrombosis …, 2004 - Elsevier
Background Small cell lung cancer (SCLC) is a chemotherapy‐responsive tumor type but
most patients ultimately experience disease progression. SCLC is associated with …
most patients ultimately experience disease progression. SCLC is associated with …
[HTML][HTML] A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer
M Altinbas, HS Coskun, O Er, M Ozkan… - Journal of Thrombosis …, 2004 - jthjournal.org
Background Small cell lung cancer (SCLC) is a chemotherapy‐responsive tumor type but
most patients ultimately experience disease progression. SCLC is associated with …
most patients ultimately experience disease progression. SCLC is associated with …
[PDF][PDF] A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer
M ALTINBAS, HS COSKUN, O ER… - Journal of Thrombosis …, 2004 - academia.edu
Background Small cell lung cancer (SCLC) is a chemotherapy-responsive tumor type but
most patients ultimately experience disease progression. SCLC is associated with …
most patients ultimately experience disease progression. SCLC is associated with …